Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis. Issue 10 (20th October 2022)

• Record Type: Journal Article
• Authors: Brennan, Xavier; Withers, Barbara; Jabbour, Andrew; Milliken, Sam; Kotlyar, Eugene; Fay, Keith; Ma, David; Muthiah, Kavitha; Hamad, Nada; Dodds, Anthony; Bart, Nikki; Keogh, Anne; Hayward, Chris; Macdonald, Peter; Moore, John
• Is Part Of: Internal medicine journal. Volume 52:Issue 10(2022)
• Page Start: 1826
• Page End: 1830
• Publication Date: 2022-10-20
• Subjects: cardiac amyloidosis -- AL amyloidosis -- heart failure -- myeloma -- bortezomib; Medicine -- Periodicals; 616
• DOI: 10.1111/imj.15926
• Languages: English
• ISSNs: 1444-0903

Abstract

Abstract: Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late‐stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.